drugset / Trial / NCT02946125

Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil

NCT02946125

Phase 2 Completed 12 enrolled Eyenovia Inc.
Non-randomizedCrossoverSingle-blindTreatment

Summary

This is a Phase 2 study to investigate the safety, efficacy and pharmacokinetics of EYN-1601 for dilation of the pupil. A single microdose of EYN-1601 will be compared to single doses of commercially available phenylephrine hydrochloride 2.5% and 10% ophthalmic solutions.

Timeline

Start
2016-10
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Phenylephrine Small molecule 2.5 % Topical
Subject Phenylephrine Small molecule 10 % Topical

Indications

No indication recorded.